

**IN THE UNITED STATES DISTRICT COURT FOR THE
DISTRICT OF NEW JERSEY**

IN RE: JOHNSON & JOHNSON)	
TALCUM POWDER PRODUCTS)	
MARKETING, SALES PRACTICES AND)	MDL Docket No. 2738
PRODUCTS LIABILITY LITIGATION)	
)	
)	
This Document Relates To All Cases)	
)	

OMNIBUS CERTIFICATION OF JULIE L. TERSIGNI

1. I am an attorney at law of the State of New Jersey and am an associate of the law firm of Drinker Biddle & Reath LLP, attorneys for Defendants Johnson & Johnson and Johnson & Johnson Consumer Inc., formerly known as Johnson & Johnson Consumer Companies, Inc. I submit this Certification based on personal knowledge in support of Defendants' Johnson & Johnson and Johnson & Johnson Consumer, Inc.'s Omnibus Motion to Exclude the Opinions of Plaintiffs' Experts for General Causation *Daubert* Hearing.

2. Attached hereto are true and correct copies of the following exhibits:

Section A: Scientific Studies, Editorials and Other Articles	
Exhibit No.	Description
A1	Abelmann et al., <i>Historical Ambient Airborne Asbestos Concentrations in the United States – An Analysis of Published and Unpublished Literature (1960s-2000s)</i> , 27(14) Inhal Toxicol. 754 (2015)

Section A: Scientific Studies, Editorials and Other Articles	
Exhibit No.	Description
A2	Acheson et al., <i>Mortality of Two Groups of Women Who Manufactured Gas Masks from Chrysotile and Crocidolite Asbestos: A 40-Year Follow-Up</i> , 39 Br J Ind Med 344 (1982)
A3	Addison & McConnell, <i>A Review of Carcinogenicity Studies of Asbestos and Non-Asbestos Tremolite and Other Amphiboles</i> , 52 Regul Toxicol Pharmacol. S180 (2008)
A4	Agency for Toxic Substances & Disease Registry, U.S. Dep't of Health & Human Servs., <i>Toxicological Profile for Cresols</i> (2008)
A5	Agency for Toxic Substances & Disease Registry, U.S. Dep't of Health & Human Servs., <i>Toxicological Profile for Nickel</i> (2005)
A6	Alberg et al., <i>Socioeconomic Status in Relation to the Risk of Ovarian Cancer in African-American Women: A Population-Based Case-Control Study</i> , 184 J. Epidemiology 274 (2016)
A7	Allaire et al., <i>Talc in Liver Tissue of Intravenous Drug Abusers with Chronic Hepatitis</i> , 92(5) A.J.C.P. 583 (1989)
A8	Amrhein et al., <i>Retire statistical significance</i> , 567 Nature 305 (2019)
A9	Baandrup et al., <i>Nonsteroidal Anti-Inflammatory Drugs and Risk of Ovarian Cancer: Systematic Review and Meta-Analysis of Observational Studies</i> , 92(3) Acta Obstet Gynecol Scand. 245 (2013)
A10	Bates et al., <i>The Challenging Pelvic Examination</i> , 26 J. Gen. Internal Med. 651 (2011)
A11	Berge et al., <i>Genital use of talc and risk of ovarian cancer: a meta-analysis</i> , 27(3) Eur J Cancer Prev. 248 (2018)
A12	Bonovas et al., <i>Do Nonsteroidal Anti-Inflammatory Drugs Affect the Risk of Developing Ovarian Cancer? A Meta-Analysis</i> , 60(2) Br J Clin Pharmacol. 194 (2005)
A13	Bosch et al., <i>The causal relation between human papillomavirus and cervical cancer</i> , 55(4) J. Clin. Pathol. 244 (2002)
A14	Brennan et al., <i>Secondhand Smoke Exposure in Adulthood and Risk of Lung Cancer Among Never Smokers: A Pooled Analysis of Two Large Studies</i> , 109 Int'l J. Cancer 125 (2004)
A15	Brydson et al., <i>Analytical Transmission Electron Microscopy</i> 3 (2014)

Section A: Scientific Studies, Editorials and Other Articles	
Exhibit No.	Description
A16	Buz'Zard & Lau, <i>Pycnogenol reduces Talc-induced Neoplastic Transformation in Human Ovarian Cancer Cultures</i> , 21 <i>Phytotherapy Res.</i> 579 (2007)
A17	Camargo et al., <i>Occupational Exposure to Asbestos and Ovarian Cancer: A Meta-Analysis</i> , 119 <i>Envtl. Health Perspectives</i> 1211 (2011)
A18	Campbell et al., Bureau of Mines, <i>Selected Silicate Minerals and Their Asbestiform Varieties</i> (1977)
A19	Center for Evidence-Based Management, <i>What are the levels of evidence?</i> , https://www.cebma.org/faq/what-are-the-levels-of-evidence/ (last visited May 1, 2019)
A20	Coggiola et al., <i>An Update of a Mortality Study of Talc Miners and Millers in Italy</i> , 44(1) <i>Am J Ind Med.</i> 63 (2003)
A21	Cook et al., <i>Perineal Powder Exposure and the Risk of Ovarian Cancer</i> , 145(5) <i>Am. J. Epidemiol.</i> 59 (1997)
A22	Cralley et al., <i>Fibrous and Mineral Content of Cosmetic Talcum Products</i> , 29(4) <i>Am Ind Hyg Assoc J.</i> 350 (1968)
A23	Cramer et al., <i>Genital Talc Exposure and Risk of Ovarian Cancer</i> , 81 <i>Int'l J. Cancer</i> 351 (1999)
A24	Cramer et al., <i>Presence of Talc in Pelvic Lymph Nodes of a Woman With Ovarian Cancer and Long-Term Genital Exposure to Cosmetic Talc</i> , 110(2) <i>Obstet Gynecol</i> 498 (2007)
A25	Cramer et al., <i>The Association Between Talc Use and Ovarian Cancer: A Retrospective Case-Control Study in Two US States</i> , 27(3) <i>Epidemiology</i> 334 (2016)
A26	De Boer, <i>Transport of Particulate Matter Through the Human Female Genital Tract</i> , 28 <i>J Reprod Fert.</i> 295 (1972)
A27	Diffraction Verification M68503-001, M68503-002, M68503-009, M68503-010, M68503-014, M68503-019, M68503-020, M68503-023, M68503-026, M68503-028, M68503-042, M68503-057, and M68503-059
A28	Diffraction Verification M69042-001, M69042-002, M69042-003, M69042-004, M69042-008, and M69042-010
A29	Diffraction Verification M69757-005 and M69757-007
A30	Egger et al., <i>Rationale, potentials, and promise of systematic reviews</i> , in <i>Systematic Reviews in Health Care: Meta-Analysis in Context</i> (M. Egger, G.D. Smith, D.G. Altman, eds. 2001)

Section A: Scientific Studies, Editorials and Other Articles	
Exhibit No.	Description
A31	Egli & Newton, <i>The Transport of Carbon Particles in the Human Female Reproductive Tract</i> , 12 Fertility & Sterility 151 (1961)
A32	Endo-Capron et al., <i>In Vitro Responses of Rat Pleural Mesothelial Cells to Talc Samples in Genotoxicity Assays</i> , 7(1) Toxicol. In Vitro 7 (1993)
A33	European Chemicals Bureau, CAS No: 81-14-1, EINECS No. 201-328-0, 4'-Tert-Butyl-2',6'-Dimethyl-3',5'-Dinitroacetophenone (Musk Ketone) <i>Summary Risk Assessment Report</i> (2005)
A34	European Commission Health & Consumer Protection Directorate-General, Sci. Committee on Health & Env'tl Risks (SCHER), <i>Opinion on Classification of Musk Ketone</i> (Jan. 2006)
A35	Ferrante et al., <i>Cancer Mortality and Incidence of Mesothelioma in a Cohort of Wives of Asbestos Workers in Casale Monferrato, Italy</i> , 115 Env'tl. Health Perspectives 1401 (2007)
A36	Ferrer et al., <i>Influence of Particle Size on Extrapleural Talc Dissemination After Talc Slurry Pleurodesis</i> , 122(3) Chest 1018 (2002)
A37	Fiume et al., <i>Safety Assessment of Talc as Used in Cosmetics</i> , 34(1 Suppl.) Int'l J Toxicol. 66S (2015)
A38	Fletcher et al., <i>Molecular Basis Supporting the Association of Talcum Powder Use with Increased Risk of Ovarian Cancer</i> (manuscript submitted Aug. 22, 2018)
A39	Fletcher et al., <i>Molecular Basis Supporting the Association of Talcum Powder Use With Increased Risk of Ovarian Cancer</i> , Reproductive Sciences (2019)
A40	Gamble & Gibbs, <i>An Evaluation of the Risks of Lung Cancer and Mesothelioma from Exposure to Amphibole Cleavage Fragments</i> , 52 Regul Toxicol Pharmacol. S154 (2008)
A41	Gardner et al., <i>Potential Delivery of Contraceptive Agents to the Female Reproductive Tract</i> , in <i>Controlled Release of Pesticides and Pharmaceuticals</i> (Lewis ed. 1981)
A42	Gates et al., <i>Risk Factors for Epithelial Ovarian Cancer by Histologic Subtype</i> , 171(1) Am J Epidemiol. 45 (2010)
A43	Gates et al., <i>Talc use, variants of the GSTM1, GSTT1, and NAT2 genes, and risk of epithelial ovarian cancer</i> , 17(9) Cancer Epidemiol Biomarkers Prev. 2436 (2008)

Section A: Scientific Studies, Editorials and Other Articles	
Exhibit No.	Description
A44	Genofre et al., <i>Talc Pleurodesis: Evidence of Systemic Inflammatory Response to Small Size Talc Particles</i> , 103 Respiratory Med. 91 (2009)
A45	Gertig et al., <i>Prospective Study of Talc Use and Ovarian Cancer</i> , 92 J. Nat. Cancer Inst. 249 (2000)
A46	Goldstein & Henifin, Fed. Judicial Ctr., <i>Reference Guide on Toxicology</i> , in <i>Reference Manual on Scientific Evidence</i> 633 (3d ed. 2011)
A47	Gonzalez et al., <i>Douching, Talc Use, and Risk of Ovarian Cancer</i> , 27(6) Epidemiol. 797 (2016)
A48	Goodman et al., <i>The nickel ion bioavailability model of the carcinogenic potential of nickel-containing substances in the lung</i> , 41(2) Crit Rev Toxicol. 142 (2011)
A49	Graham & Graham, <i>Ovarian cancer and asbestos</i> , 1 Env'tl Res. 115 (1967)
A50	Grant et al., <i>Primary Peritoneal and Ovarian Cancers: An Epidemiological Comparative Analysis</i> , 21 Cancer Causes Control 991 (2010)
A51	Green et al., Fed. Judicial Ctr., <i>Reference Guide on Epidemiology</i> , in <i>Reference Manual on Scientific Evidence</i> 549 (3d ed. 2011)
A52	Gualtieri, <i>Towards a quantitative model to predict the toxicity/pathogenicity potential of mineral fibers</i> , 361 Toxicol. & Applied Pharmacol. 89 (2018)
A53	Hamilton et al., <i>Effects of Talc on the Rat Ovary</i> , 65 Br. J. Exp. Pathol. 101 (1984)
A54	Hanchette et al., <i>Ovarian Cancer Incidence in the U.S. and Toxic Emissions from Pulp and Paper Plants: A Geospatial Analysis</i> , 15 Int'l J. Env'tl. Res. Pub. Health 1619 (2018)
A55	Harlow et al., <i>Perineal Exposure to Talc and Ovarian Cancer</i> , 80(1) Obstet Gynecol. 19, 22 (1992)
A56	Hartge et al., <i>Talc and Ovarian Cancer</i> , 250(14) J. Am. Med. Assoc., 1844 (1983)
A57	Health Canada, <i>Application of Weight of Evidence and Precaution in Risk Assessment</i> , https://www.canada.ca/en/health-canada/services/chemical-substances/fact-sheets/application-weight-of-evidence-precaution-risk-assessments.html (last updated June 15, 2017)

Section A: Scientific Studies, Editorials and Other Articles	
Exhibit No.	Description
A58	Health Canada, Draft Screening Assessment: Talc ($\text{Mg}_3\text{H}_2(\text{SiO}_3)_4$) (Chem. Abstracts Serv. Registry No. 14807-96-6) (2018)
A59	Heller et al., <i>Asbestos Exposure and Ovarian Fiber Burden</i> , 29 Am. J. Indus. Med. 434 (1996)
A60	Heller et al., <i>The Relationship Between Perineal Cosmetic Talc Usage and Ovarian Talc Particle Burden</i> , Am. J. Obstet Gynecol 1507 (1996)
A61	Henderson et al., <i>Talc and Carcinoma of the Ovary and Cervix</i> , J Obstet Gynaecol Br Commonw. 266 (1971)
A62	Henderson et al., <i>The Demonstration of the Migration of Talc from the Vagina and Posterior Uterus to the Ovary in the Rat</i> , 40 Enviro. Res. 247 (1986)
A63	Hill, <i>The Environment and Disease: Association or Causation?</i> , 58(5) Proc. Royal Soc'y Med. 295 (1965)
A64	Hillegass et al., <i>Utilization of Gene Profiling and Proteomics to Determine Mineral Pathogenicity in a Human Mesothelial Cell Line</i> , 73(5) J. Toxicol. Env'tl. Health A 423 (2010)
A65	Houghton et al., <i>Perineal Powder Use and Risk of Ovarian Cancer</i> , 106(9) J. Nat. Cancer Inst. (2014)
A66	Hsie et al., <i>The Use of Chinese Hamster Ovary Cells to Quantify Specific Locus Mutation and to Determine Mutagenicity of Chemicals. A Report of the Gene-Tox Program</i> , 86(2) Mutat Res. 193 (1981)
A67	Huncharek et al., <i>Perineal Application of Cosmetic Talc and Risk of Invasive Epithelial Ovarian Cancer: A Meta-Analysis of 11,933 Subjects from Sixteen Observational Studies</i> , 23 Anticancer Res. 1955 (2003)
A68	Huncharek et al., <i>Use of Cosmetic Talc on Contraceptive Diaphragms and Risk of Ovarian Cancer: A Meta-Analysis of Nine Observational Studies</i> , 16 Eur J Cancer Prev. 422 (2007)
A69	Index of IFRA Standards – 48th Amendment
A70	Int'l Agency for Research on Cancer, World Health Org., 100C <i>Monographs on the Evaluation of Carcinogenic Risks to Humans: Arsenic, Metals, Fibres, and Dust</i> (2012)

Section A: Scientific Studies, Editorials and Other Articles	
Exhibit No.	Description
A71	Int'l Agency for Research on Cancer, World Health Org., 49 <i>Monographs on the Evaluation of Carcinogenic Risks to Humans: Chromium, Nickel and Welding</i> (1990) [excerpts]
A72	Int'l Agency for Research on Cancer, World Health Org., 93 <i>Monographs on the Evaluation of Carcinogenic Risks to Humans: Carbon Black, Titanium Dioxide, and Talc</i> (2010)
A73	Int'l Agency for Research on Cancer, World Health Org., <i>Monograph on the Evaluation of Carcinogenic Risks to Humans: Preamble</i> (2006)
A74	Int'l Org. for Standardization, <i>Air Quality – Bulk Materials: Part 1: Sampling and qualitative determination of asbestos in commercial bulk materials</i> (2012)
A75	Int'l Org. for Standardization, <i>Air Quality – Bulk Materials: Part 2: Quantitative determination of asbestos by gravimetric and microscopical methods</i> (2014)
A76	Int'l Org. for Standardization, <i>Ambient Air – Determination of asbestos fibres – Direct-transfer transmission electron microscopy method</i> (1995)
A77	International Organization for Standardization, <i>All about ISO</i> , https://www.iso.org/about-us.html (last visited May 4, 2019)
A78	International Organization for Standardization, <i>ANSI</i> , https://www.iso.org/member/2188.html (last visited May 4, 2019)
A79	Ioannidis et al., <i>The Importance of Predefined Rules and Prespecified Statistical Analyses: Do Not Abandon Significance</i> , JAMA Online (2019), https://jamanetwork.com/journals/jama/fullarticle/2730486
A80	Iturralde & Venter, <i>Hysterosalpingo-Radionuclide Scintigraphy (HERS)</i> , 9(4) Seminars in Nuclear Med. 301 (1981)
A81	Johnson, <i>Retiring Significance: Raise the Bar</i> , 567 Nature 461 (2019)
A82	Jones & Lopez, <i>Gamete Transportation and Fertilization</i> , in <i>Human Reproductive Biology</i> (3d ed. 2006)
A83	Kadanali et al., <i>Evaluation of active and passive transport mechanisms in genital tracts of IUD-bearing women with radionuclide hysterosalpingoscintigraphy</i> , 63 Contraception 41 (2001)

Section A: Scientific Studies, Editorials and Other Articles	
Exhibit No.	Description
A84	Karageorgi et al., <i>Perineal Use of Talcum Powder and Endometrial Cancer Risk</i> , 19(5) Cancer Epidemiol Biomarkers Prev. 1269 (2010)
A85	Keskin et al., <i>Does Long-Term Talc Exposure Have a Carcinogenic Effect on the Female Genital System of Rats? An experimental pilot study</i> , 280 Archives Gynecol. Obstet. 925 (2009)
A86	Kunz et al., <i>The Uterine Peristaltic Pump: Normal and Impeded Sperm Transport within the Female Genital Tract</i> , in <i>The Fate of the Male Germ Cell</i> 267 (Ivell & Holstein eds. 1997)
A87	Langseth & Kjaerheim, <i>Ovarian cancer and occupational exposure among pulp and paper employees in Norway</i> , 30(5) Scand. J. Work Envtl. Health 356 (2004)
A88	Langseth et al., <i>Perineal Use of Talc and Risk of Ovarian Cancer</i> , 62 J. Epidemiology & Cmty. Health 358 (2008)
A89	Letter from Steven M. Musser, Ph.D., Deputy Dir. for Sci. Operations, Ctr. for Food Safety & Applied Nutrition, to Samuel S. Epstein, M.D., Cancer Prev. Coalition, Univ. of Ill. – Chi. School of Pub. Health (Apr. 1, 2014)
A90	Lin et al., <i>Risk of Ovarian Cancer in Women with Pelvic Inflammatory Disease: A Population-Based Study</i> , 12(9) Lancet Oncol. 900 (2011)
A91	Malmberg et al., <i>Serous tubal intraepithelial carcinoma, chronic fallopian tube injury, and serous carcinoma development</i> , 468 Virchows Arch. 707 (2016)
A92	MAS TEM Coefficient of Variation for Tremolite and Anthophyllite in Talc: A Quality Control Study, Sept. 6, 2018
A93	McDonald et al., <i>Correlative polarizing light and scanning electron microscopy for the assessment of talc in pelvic region lymph nodes</i> , 43 Ultrastructural Pathol. 1 (2019)
A94	Mills et al., <i>Perineal talc exposure and epithelial ovarian cancer risk in the Central Valley of California</i> , 112(3) Int'l J. Cancer 458 (2004)
A95	Moorman et al., <i>Ovarian Cancer Risk Factors in African-American and White Women</i> , 170(5) Am J Epidemiol. 598 (2009)
A96	Morice et al., <i>Mucinous Ovarian Carcinoma</i> , 380(13) N. Engl. J. Med. 1256 (2019)

Section A: Scientific Studies, Editorials and Other Articles	
Exhibit No.	Description
A97	Narod, <i>Talc and Ovarian Cancer</i> , 141(3) Gynecol. Oncol. 410 (2016)
A98	Nat'l Inst. for Occupational Health and Safety, <i>Asbestos Fibers and Other Elongate Mineral Particles: State of the Science and Roadmap for Research</i> (2011)
A99	Nat'l Toxicology Program, Organ Sites with Neoplasia Guided Search Health, https://manticore.niehs.nih.gov/cebssearch/support/view/CEBS_Organ-Sites-Neoplasia-Guided-Search-Help.pdf (last updated July 21, 2017)
A100	Nat'l Toxicology Program, U.S. Dep't of Health & Human Servs., No. 389, <i>Toxicology and Carcinogenesis Studies of Sodium Azide (CAS No. 26628-22-8) in F344/N Rats (Gavage Studies)</i> (1991)
A101	Nat'l Toxicology Program, U.S. Dep't of Health & Human Servs., No. 451, <i>Toxicology and Carcinogenesis of Nickel Oxide (CAS No. 1313-99) in F344/N Rats and B6C3F1 Mice (Inhalation Studies)</i> (1996)
A102	Nat'l Toxicology Program, U.S. Dep't of Health & Human Servs., No. 453, <i>Toxicology and Carcinogenesis of Nickel Subsulfide (CAS No. 12035-72-2) in F344/N Rats and B6C3F1 Mice (Inhalation Studies)</i> (1996)
A103	Nat'l Toxicology Program, U.S. Dep't of Health & Human Servs., No. 454, <i>Toxicology and Carcinogenesis Studies of Nickel Sulfate Hexahydrate (CAS No. 10101-97-0) in F344 Rats and B6C3F1 Mice (Inhalation Studies)</i> (1996)
A104	Nat'l Cancer Inst., <i>Ovarian, Fallopian Tube, and Primary Peritoneal Cancer Prevention (PDQ®)–Health Professional Version</i> , https://www.cancer.gov/types/ovarian/hp/ovarian-prevention-pdq (last updated Mar. 1, 2019)
A105	Ness & Cottreau, <i>Review: Possible Role of Ovarian Epithelial Inflammation in Ovarian Cancer</i> , 91(17) J. Nat'l Cancer Inst. 1459 (1999)
A106	Ness et al., <i>Factors Related to Inflammation of the Ovarian Epithelium and Risk of Ovarian Cancer</i> , 11 Epidemiol. 111 (2000)

Section A: Scientific Studies, Editorials and Other Articles	
Exhibit No.	Description
A107	Ni et al., <i>Meta-Analysis on the Association Between Non-Steroidal Anti-Inflammatory Drug Use and Ovarian Cancer</i> , 75(1) Br J Clin Pharmacol. 26 (2012)
A108	Orden et al., <i>Small Particle-Size Talc Is Associated with Poor Outcome and Increased Inflammation in Thoracoscopic Pleurodesis</i> , 86 Respiration 201 (2013)
A109	Penninkilampi & Eslick, <i>Perineal Talc Use and Ovarian Cancer: A Systematic Review and Meta-Analysis</i> , 29 Epidemiol. 41 (2018)
A110	Peres et al., <i>Analgesic Medication Use and Risk of Epithelial Ovarian Cancer in African-American Women</i> , 114 Br J Cancer 819 (2016)
A111	Peres et al., <i>Racial/ethnic differences in the epidemiology of ovarian cancer: a pooled analysis of 12 case-control studies</i> , Int'l J Epidemiol. 1 (2017)
A112	Perkins & Harvey, U.S. Env't'l Protection Agency, <i>Test Method: Method for the Determination of Asbestos in Bulk Building Materials</i> (1993)
A113	Phillips et al., <i>Studies on the Absorption and Disposition of 3H-Labelled Talc in the Rat, Mouse, Guinea-Pig and Rabbit</i> , 16 Toxicol. 161 (1978)
A114	Pike et al., <i>Hormonal Factors and the Risk of Invasive Ovarian Cancer: A Population-Based Case-Control Study</i> , 82(1) Fertility & Sterility 186 (2004)
A115	Qin et al., <i>Dietary Quality and Ovarian Cancer Risk in African-American Women</i> , 185 J Epidemiol. 1281 (2017)
A116	Rasmussen et al., <i>Pelvic Inflammatory Disease and the Risk of Ovarian Cancer and Borderline Ovarian Tumors: A Pooled Analysis of 13 Case-Control Studies</i> , 185(1) Am J Epidemiol. 8 (2017)
A117	Reid et al., <i>Cancer Incidence Among Women and Girls Environmentally and Occupationally Exposed to Blue Asbestos at Wittenoom, Western Australia</i> , 122 Int'l J. Cancer 2337 (2008)
A118	Reid et al., <i>Does Exposure to Asbestos Cause Ovarian Cancer? A Systematic Literature Review and Meta-Analysis</i> , 20(7) Cancer Epidemiol Biomarkers Prev. 1287 (2011)

Section A: Scientific Studies, Editorials and Other Articles	
Exhibit No.	Description
A119	Reid et al., <i>Gynecologic and Breast Cancers in Women After Exposure to Blue Asbestos at Wittenoom</i> , 18 Cancer Epidemiol. Biomarkers Prev. 140 (2009)
A120	Reuter et al., <i>Oxidative Stress, Inflammation and Cancer: How Are They Linked?</i> , 49 Free Radical Bio. Med. 1603 (2010)
A121	Rhodes et al., <i>Carcinogenesis studies of benzophenone in rats and mice</i> , 45(5) Food Chem Toxicol. 843 (2007)
A122	Robert-Sauve Research Institute in Occupational Health and Safety, <i>Studies and Research Projects: Synthesis of Knowledge on Tremolite in Talc (Report R-755)</i> (2012)
A123	Roggli & Green, <i>Dimensions of Elongated Mineral Particles: A Study of More Than 570 Fibers From More Than 90 Cases with Implications for Pathogenicity and Classification as Asbestiform vs. Cleavage Fragments</i> , Ultrastruct Pathol. 1 (2019)
A124	Rosenblatt et al., <i>Characteristics of Women Who Use Perineal Powders</i> , 92(5) Obstet Gynecol. 753 (1998)
A125	Rosenblatt et al., <i>Genital Powder Exposure and the Risk of Epithelial Ovarian Cancer</i> , 25(2) Cancer Causes Control 737 (2011)
A126	Rothman et al., <i>Interpretation of Epidemiologic Studies on Talc and Ovarian Cancer</i> (2000)
A127	Saed et al., <i>Dichloroacetate Induces Apoptosis of Epithelial Ovarian Cancer Cells Through a Mechanism Involving Modulation of Oxidative Stress</i> , 18 Reprod. Sci. 1253 (2011)
A128	Saed et al., <i>Updates on the Role of Oxidative Stress in the Pathogenesis of Ovarian Cancer</i> , 145 Gynecol. Oncol. 595 (2017)
A129	Schildkraut et al., <i>Association between Body Powder Use and Ovarian Cancer: The African American Cancer Epidemiology Study</i> , 25(10) Cancer Epidemiol Biomarkers Prev. (2016)
A130	Senthil et al., <i>Evidence of Oxidative Stress in the Circulation of Ovarian Cancer Patients</i> , 339 Clinica Chimica Acta 27 (2004)
A131	Shukla et al., <i>Alterations in Gene Expression in Human Mesothelial Cells Correlate with Mineral Pathogenicity</i> , 41 Am. J. Respiratory Cell Molecular Biology 114 (2009)
A132	<i>Significant debate</i> , 567 Nature 283 (Mar. 21, 2019)

Section A: Scientific Studies, Editorials and Other Articles	
Exhibit No.	Description
A133	Silbergeld, <i>The Role of Toxicology in Causation: A Scientific Perspective</i> , 1 Courts. Health Sci. & L. 374 (1991)
A134	Sjösten et al., <i>Retrograde migration of glove powder in human female genital tract</i> , 19 Hum. Reprod. 991 (2004)
A135	Smith et al., <i>Biologic Tests of Tremolite in Hamsters</i> , Dusts Disease 335 (1979)
A136	Stanton et al., <i>Relation of Particle Dimension to Carcinogenicity in Amphibole Asbestoses and other Fibrous Minerals</i> , 67(3) J. Nat'l Cancer Inst. 965 (1981)
A137	Taher et al., <i>Systematic Review and Meta-Analysis of the Association Between Perineal Use of Talc and Risk of Ovarian Cancer</i> (unpublished, 2018)
A138	Taylor et al., <i>Meta-analysis of studies of passive smoking and lung cancer: effects of study type and continent</i> , 36 Int'l J. Epidemiol. 1048 (2007)
A139	Terry et al., <i>Genital Powder Use and Risk of Ovarian Cancer: A Pooled Analysis of 8,525 Cases and 9,859 Controls</i> , 6(8) Cancer Prevention Res. 811 (2013)
A140	Terry et al., <i>Supplemental Selenium May Decrease Ovarian Cancer Risk in African-American Women</i> , 147 J. Nutrition 621 (2017)
A141	Trabert et al., <i>Analgesic Use and Ovarian Cancer Risk: An Analysis in the Ovarian Cancer Cohort Consortium</i> , 111(2) J. Nat'l Cancer Inst. 137 (2019)
A142	Trabert et al., <i>Aspirin, Nonaspirin Nonsteroidal Anti-Inflammatory Drug, and Acetaminophen Use and Risk of Invasive Epithelial Ovarian Cancer: A Pooled Analysis in the Ovarian Cancer Association Consortium</i> , 106(2) J. Nat'l Cancer Inst. 1 (2014)
A143	Trabert et al., <i>Pre-Diagnostic Serum Levels of Inflammation Markers and Risk of Ovarian Cancer in the Prostate, Lung, Colorectal and Ovarian Cancer (PLCO) Screening Trial</i> , 135 Gynecol Oncol. 297 (2014)
A144	U.S. Env'tl. Protection Agency, CAS No. 18540-29-9, <i>Toxicological Review of Hexavalent Chromium</i> (1998)
A145	U.S. Env'tl. Protection Agency, <i>Integrated Risk Information System, 4-Methylphenol; CASN 106-44-5</i> 4 (1993),

Section A: Scientific Studies, Editorials and Other Articles	
Exhibit No.	Description
	https://cfpub.epa.gov/ncea/iris/iris_documents/documents/subst/0302_summary.pdf
A146	U.S. Geological Survey, <i>Some Facts About Asbestos</i> (2001)
A147	U.S. Geological Survey, Tremolite Images Nos. 2, 18, 20
A148	Ventner & Iturralde, <i>Migration of a Particulate Radioactive Tracer from the Vagina to the Peritoneal Cavity and Ovaries</i> , SA Med. J. 917 (1979)
A149	Wehner et al., <i>On Talc Translocation From the Vagina to the Oviducts and Beyond</i> , 24 Food Chem Toxicol. 329 (1986)
A150	Werebe et al., <i>Systemic Distribution of Talc After Intrapleural Administration in Rats</i> , 115(1) Chest 190 (1999)
A151	Wergeland et al., <i>Morbidity and Mortality in Talc-Exposed Workers</i> , 17(4) Am J Ind Med. 505 (1990)
A152	Wild et al., <i>A Cohort Mortality and Nested Case-Control Study of French and Austrian Talc Workers</i> , 59(2) Occup Environ Med. 98 (2002)
A153	World Cancer Res. Fund & Am. Inst. for Cancer Res., <i>Continuous Update Project Expert Report: Judging the Evidence</i> (2018)
A154	World Cancer Res. Fund Int'l Continuous Update Project, <i>Diet, Nutrition, Physical Activity and Ovarian Cancer</i> (revised 2018)
A155	Wu et al., <i>African Americans and Hispanics Remain at Lower Risk of Ovarian Cancer Than Non-Hispanic Whites after Considering Nongenetic Risk Factors and Oophorectomy Rates</i> , 24(7) Cancer Epidemiology Biomarkers Prev. 1094 (2015)
A156	Wylie et al., <i>Mineralogical Features Associated with Cytotoxic and Proliferative Effects of Fibrous Talc and Asbestos on Rodent Tracheal Epithelial and Pleural Mesothelial Cells</i> , 147 Toxicol. Applied Pharmacol. 143 (1997)
A157	Wynder et al., <i>Weak Associations in Epidemiology and Their Interpretation</i> , 11 Preventive Med. 464 (1982)
A158	Yamate et al., <i>Methodology for the Measurement of Airborne Asbestos by Electron Microscopy</i> (1984)
A159	Zervomanolakis et al., <i>Physiology of Upward Transport in the Human Female Genital Tract</i> , 1101 Ann. N.Y. Acad. Sci. 1 (2007)

Section B: MDL Depositions and Exhibits ¹	
Exhibit No.	Description
B1	Deposition of Alan Campion, Ph.D., Jan. 9, 2019
B2	Deposition of Anne McTiernan, M.D., Ph.D., Jan. 28, 2019
B3	Deposition of April Zambelli-Weiner, Ph.D. Vol. I, Jan. 11, 2019
B4	Deposition of April Zambelli-Weiner, Ph.D. Vol. II, Feb. 7, 2019
B5	Deposition of Arch I. Carson, M.D., Ph.D., Jan. 19, 2019
B6	Deposition of Benjamin Neel, M.D., Ph.D., Mar. 19, 2019
B7	Deposition of Brooke T. Mossman, M.S., Ph.D., Apr. 8, 2019
B8	Deposition of Brooke T. Mossman, M.S., Ph.D., Exhibit 24
B9	Deposition of Christian Merlo, M.D., M.P.H., Apr. 18, 2019
B10	Deposition of Daniel L. Clarke-Pearson, M.D., Feb. 4, 2019
B11	Deposition of Ellen Blair Smith, M.D., Jan. 9, 2019
B12	Deposition of Ghassan Saed, Ph.D. Vol. 1, Jan. 23, 2019
B13	Exhibit 1 to Deposition of Ghassan Saed, Ph.D. Vol. 1; and produced version of SAED000001-97(color) also attached
B14	Exhibit 8 to Deposition of Ghassan Saed, Ph.D. Vol. 1
B15	Exhibit 9 to Deposition of Ghassan Saed, Ph.D. Vol. 1; and produced version of Abstract Lab Notes also attached
B16	Exhibit 19 to Deposition of Ghassan Saed, Ph.D. Vol. 1
B17	Exhibit 20 to Deposition of Ghassan Saed, Ph.D. Vol. 1
B18	Exhibit 21 to Deposition of Ghassan Saed, Ph.D. Vol. 1
B19	Deposition of Ghassan Saed, Ph.D. Vol. 2, Feb. 14, 2019
B20	Exhibit 23 to Deposition of Ghassan Saed, Ph.D. Vol. 2; and produced version of Pilot Study Lab Notes also attached
B21	Exhibit 31 to Deposition of Ghassan Saed, Ph.D. Vol. 2
B22	Exhibit 33 to Deposition of Ghassan Saed, Ph.D. Vol. 2
B23	Exhibit 35 to Deposition of Ghassan Saed, Ph.D. Vol. 2
B24	Exhibit 39 to Deposition of Ghassan Saed, Ph.D. Vol. 2
B25	Exhibit 44 to Deposition of Ghassan Saed, Ph.D. Vol. 2
B26	Deposition of Gregory Diette, M.D., Apr. 9, 2019
B27	Deposition of H. Nadia Moore, Ph.D., Apr. 4, 2019
B28	Deposition of Ie-Ming Shih, M.D., Ph.D., Mar. 26, 2019
B29	Deposition of Jack Siemiatycki, Ph.D., Jan. 31, 2019
B30	Deposition of Judith K. Wolf, M.D., Jan. 7, 2019

¹ Relevant excerpts have been highlighted for the Court.

Section B: MDL Depositions and Exhibits ¹	
Exhibit No.	Description
B31	Deposition of Judith Zelikoff, Ph.D., Jan. 21, 2019
B32	Deposition of Karla Ballman, Ph.D., Mar. 22, 2019
B33	Deposition of Laura Plunkett, Ph.D., D.A.B.T., Dec. 19, 2018
B34	Deposition of Mark Krekeler, Ph.D., Jan. 25, 2019
B35	Deposition of Mark W. Rigler, Ph.D., Feb. 6, 2019
B36	Deposition of Michael Birrer, M.D., Ph.D., Mar. 29, 2019
B37	Deposition of Michael Crowley, Ph.D., Jan. 4, 2019
B38	Exhibit 18 to Deposition of Michael Crowley, Ph.D.
B39	Deposition of Patricia G. Moorman, M.S.P.H., Ph.D., Jan. 25, 2019
B40	Deposition of Rebecca Smith-Bindman, M.D. Vol. I, Feb. 7, 2019
B41	Exhibit 24 to Deposition of Rebecca Smith-Bindman, M.D. Vol. I
B42	Deposition of Rebecca Smith-Bindman, M.D. Vol. II, Feb. 8, 2019
B43	Deposition of Robert Cook, Ph.D., Jan. 30, 2019
B44	Deposition of Robert Kurman, M.D., Apr. 2, 2019
B45	Deposition of Sarah E. Kane, M.D., Jan. 25, 2019
B46	Deposition of Shawn Levy, Ph.D., Jan. 11, 2019
B47	Deposition of Sonal Singh, M.D., M.P.H., Jan. 16, 2019
B48	Deposition of William E. Longo, Ph.D., Feb. 5, 2019
B49	Exhibit 12 to Deposition of William E. Longo, Ph.D.

Section C: MDL Expert Reports and CVs	
Exhibit No.	Description
C1	Second Supplemental Expert Report of William E. Longo, Ph.D. & Mark W. Rigler, Ph.D., Feb. 1, 2019
C2	Amended Expert Report of Robert B. Cook, Ph.D., Jan. 22, 2019
C3	Curriculum Vitae of Dr. Mark W. Rigler, Ph.D.
C4	Curriculum Vitae of Dr. William E. Longo, Ph.D.
C5	Expert Report of Alan Campion, Ph.D., Nov. 16, 2018
C6	Expert Report of Ann G. Wylie, Ph.D., Feb. 25, 2019
C7	Expert Report of Anne McTiernan, M.D., Ph.D., Nov. 16, 2018
C8	Expert Report of April Zambelli-Weiner, Ph.D., M.P.H., Nov. 16, 2018
C9	Expert Report of Arch Carson, M.D., Ph.D., Nov. 16, 2018
C10	Expert Report of Benjamin G. Neel, M.D., Ph.D., Feb. 25, 2019

Section C: MDL Expert Reports and CVs	
Exhibit No.	Description
C11	Expert Report of Brooke Taylor Mossman, M.S., Ph.D., Feb. 25, 2019
C12	Expert Report of Cheryl Christine Saenz, M.D., Feb. 25, 2019
C13	Expert Report of Christian Merlo, M.D., M.P.H., Feb. 25, 2019
C14	Expert Report of Daniel L. Clarke-Pearson, M.D., Nov. 16, 2018
C15	Expert Report of David A. Kessler, M.D., Nov. 16, 2018
C16	Expert Report of Ellen Blair Smith, M.D., Nov. 16, 2018
C17	Expert Report of Ghassan Saed, Ph.D., Nov. 16, 2018
C18	Expert Report of Gregory Diette, M.D., M.H.S., Feb. 25, 2019
C19	Expert Report of H. Nadia Moore, Ph.D., D.A.B.T., E.R.T., Feb. 25, 2019 [Portions redacted pursuant to Discovery Confidentiality Order dated March 1, 2017]
C20	Expert Report of Ie-Ming Shih, M.D., Ph.D., Feb. 25, 2019
C21	Expert Report of Jack Siemiatycki, M.Sc., Ph.D., Nov. 16, 2018
C22	Expert Report of Jeff Boyd, Ph.D., Feb. 25, 2019
C23	Expert Report of Judith Wolf, M.D., Nov. 16, 2018
C24	Expert Report of Judith Zelikoff, Ph.D., Nov. 16, 2018
C25	Expert Report of Karla Ballman, Ph.D., Feb. 25, 2019
C26	Expert Report of Kelly Scribner Tuttle, Ph.D., C.I.H., Feb. 25, 2019 [Portions redacted pursuant to Discovery Confidentiality Order dated March 1, 2017]
C27	Expert Report of Kevin Holcomb, M.D., F.A.C.O.G., Feb. 25, 2019
C28	Expert Report of Laura M. Plunkett, Ph.D., D.A.B.T., Nov. 16, 2018
C29	Expert Report of Laura Webb, Ph.D., Feb. 25, 2019
C30	Expert Report of M. Darby Dyar, Ph.D., Feb. 25, 2019
C31	Expert Report of Mark Krekeler, Ph.D., Nov. 16, 2018
C32	Expert Report of Mary Poulton, Ph.D., Feb. 25, 2019
C33	Expert Report of Michael Birrer, M.D., Ph.D., Feb. 25, 2019
C34	Expert Report of Michael M. Crowley, Ph.D., Nov. 12, 2018 [Portions redacted pursuant to Discovery Confidentiality Order dated March 1, 2017]
C35	Expert Report of Patricia G. Moorman, M.S.P.H., Ph.D., Nov. 16, 2018
C36	Expert Report of Rebecca Smith-Bindman, M.D., Nov. 15, 2018
C37	Expert Report of Robert J. Kurman, M.D., Feb. 25, 2019

Section C: MDL Expert Reports and CVs	
Exhibit No.	Description
C38	Expert Report of Sarah E. Kane, M.D., Nov. 15, 2018
C39	Expert Report of Shawn Levy, Ph.D., Nov. 16, 2018
C40	Expert Report of Sonal Singh, M.D., M.P.H., Nov. 16, 2018
C41	Excerpts of the Expert Report of William E. Longo, Ph.D. & Mark W. Rigler, Ph.D., Nov. 14, 2018

Section D: Produced Documents	
Exhibit No.	Description
D1	JNJ_000245002-148
D2	JNJ000322351-475
D3	JNJ000085376-78
D4	JNJTALC000147667-68
D5	JNJTALC000294523-24
D6	JNJTALC000891091-104
D7	JNJTALC001021615-16

Section E: Non-MDL Depositions, Transcripts, Expert Reports and Court Filings²	
Exhibit No.	Description
E1	Excerpts of the Deposition of Jack Siemiatycki, Ph.D., <i>Oules v. Johnson & Johnson</i> , No. 2014 CA 088327 B (D.C. Super. Ct. Dec. 16, 2016)
E2	Excerpts of the Deposition of Patricia Moorman, Ph.D., M.S.P.H., <i>Ingham v. Johnson & Johnson</i> , No. 1522-CC10417-01 (Mo. Cir. Ct. Mar. 12, 2018)
E3	Excerpts of the Deposition of William E. Longo, Ph.D., <i>Anderson v. Borg-Warner Corp.</i> , No. BC666513, JCCP No. 5674 (Cal. Super. Ct. Mar. 29, 2018)
E4	Excerpts of the Deposition of William E. Longo, Ph.D., <i>Herford v. AT&T Corp.</i> , No. BC646315 (Cal. Super. Ct. Aug. 23, 2017)

² Relevant testimony in trial transcripts and deposition transcripts is highlighted for the Court.

Section E: Non-MDL Depositions, Transcripts, Expert Reports and Court Filings²	
Exhibit No.	Description
E5	Excerpts of the Deposition of William E. Longo, Ph.D., <i>In re Kelvin Manbodh Asbestos Litig.</i> , No. 324/1997 (V.I. Terr. Ct. May 28, 2002)
E6	Excerpts of the Deposition of William E. Longo, Ph.D., <i>Rimondi v. BASF Catalysts LLC</i> , No. MID-L-2912-17 (N.J. Super. Ct. Law Div. Jan. 7, 2019)
E7	Excerpts of the Deposition of William E. Longo, Ph.D., <i>Starkweather v. ACandS, Inc.</i> , No. 00-6030 (Mass. Super Ct. July 18, 2002)
E8	Excerpts of the Deposition of William E. Longo, Ph.D., <i>Von Salzen v. American Int'l Indus. Inc.</i> , No. BC6805786 (Cal. Super. Ct. June 27, 2018)
E9	Excerpts of the Deposition of William E. Longo, Ph.D., <i>Weirick v. Brenntag N. Am., Inc.</i> , No. BC656425 (Cal. Super. Ct. Apr. 17, 2018)
E10	Excerpts of the Deposition of William E. Longo, Ph.D., <i>Weirick v. Brenntag N. Am., Inc.</i> , No. BC656425 (Cal. Super. Ct. Apr. 17, 2019)
E11	Excerpts of the Deposition of William E. Longo, Ph.D., <i>Wittman v. Brenntag N. Am., Inc.</i> , No. BC646439 (Cal. Super. Ct. Nov. 20, 2017)
E12	Excerpts of the Deposition of William E. Longo, Ph.D., <i>Young v. Johnson & Johnson</i> , No. 1522-CC09728-02 (Mo. Cir. Ct. Jan. 25, 2019)
E13	Expert Report of Jack Siemiatycki M.Sc., Ph.D. on Talc Use and Ovarian Cancer (Oct. 4, 2016) (submitted in <i>Lloyd v. Johnson & Johnson (Plaintiff Eva Echeverria only)</i> , No. BC628228 (JCCP No. 4872) (Cal. Super Ct.)
E14	Excerpts of the Longo & Rigler, Suppl. Expert Report & Analysis of Johnson & Johnson Baby Powder and Valeant Shower to Shower Talc Products for Amphibole Asbestos, <i>Ingham v. Johnson & Johnson</i> , No. 1522-CC10417-01 (Mo. Cir. Ct. Mar. 11, 2018)
E15	Order Ex. A, <i>In re Lamar Cty. Asbestos Litig.</i> , No. 2000-3559 (Tex. Dist. Ct. July 5, 2001)

Section E: Non-MDL Depositions, Transcripts, Expert Reports and Court Filings²	
Exhibit No.	Description
E16	Rulings on Motions in <i>Limine</i> Ex. B, <i>Weirick v. Brenntag N. Am., Inc.</i> , No. BC656425 (Cal. Super. Ct. July 23, 2018)
E17	Tentative Ruling Permitting Dr. Plunkett's Opinions in Part, <i>Lloyd v. Johnson & Johnson</i> , No. BC628228, JCCP No. 4872 (Cal. Super. Ct.)
E18	Excerpts of Transcript of Proceedings, <i>Allen v. Brenntag N. Am., Inc.</i> , No. DR 180132 (Cal. Super. Ct. Oct. 1, 2018)
E19	Excerpts of Transcript of Proceedings (A.M. Session), <i>Herford v. AT&T Corp.</i> , No. BC646315, JCCP 4674 (Cal. Super. Ct. Oct. 25, 2017)
E20	Excerpts of Trial Transcript, <i>Anderson v. Borg-Warner Corp.</i> , No. BC666513, JCCP No. 5674 (Cal. Super. Ct. May 15, 2018)
E21	Excerpts of Trial Transcript, <i>Allen v. Brenntag N. Am., Inc.</i> , No. DR180132 (Cal. Super. Ct. Oct. 17, 2018)
E22	Excerpts of Trial Transcript, <i>Allen v. Brenntag N. Am., Inc.</i> , No. DR180132 (Cal. Super. Ct. Oct. 19, 2018)
E23	Excerpts of Trial Transcript, <i>Brick v. Brenntag N. Am., Inc.</i> , No. BC674595 (Cal. Super. Ct. May 31, 2018)
E24	Excerpts of Trial Transcript, <i>Henry v. Brenntag N. Am., Inc.</i> , No. MID-1748-17AS (N.J. Super. Ct. Law Div. Oct. 10, 2018)
E25	Excerpts of Trial Transcript, <i>Leavitt v. Johnson & Johnson</i> , No. RG17882401 (Cal. Super. Ct. Feb. 7, 2019)
E26	Excerpts of Trial Transcript, <i>Leavitt v. Johnson & Johnson</i> , No. RG17882401 (Cal. Super. Ct. Feb. 14, 2019)
E27	Excerpts of Trial Transcript, <i>Ingham v. Johnson & Johnson</i> , No. 1522-CC10417-01 (Mo. Cir. Ct. June 8, 2018)
E28	Excerpts of Trial Transcript, <i>Olson v. Brenntag N. Am.</i> , No. 190328 (N.Y. Sup. Ct. Feb. 26, 2019)
E29	Excerpts of Trial Transcript, <i>Rimondi v. BASF Catalysts LLC</i> , No. MID-L-2912-17 (N.J. Super. Ct. Law Div. Mar. 5, 2019)
E30	Excerpts of Trial Transcript, <i>Russell v. Janssen Res. & Dev. LLP</i> , No. 150500362 (Phila. Ct. Comm. Pls. Apr. 12, 2018)
E31	Excerpts of Trial Transcript, <i>Weirick v. Brenntag N. Am., Inc.</i> , No. BC656425 (Cal. Super. Ct. Aug. 24, 2018)

Section F: Plaintiffs' Experts' Communications with Health Canada	
Exhibit No.	Description
F1	Email Submission of Anne McTiernan, M.D., Ph.D. to Health Canada, Feb. 5, 2019
F2	Letter from Jack Siemiatycki, M.Sc., Ph.D. to Health Canada, Feb. 6, 2019
F3	Email Exchange between Anne McTiernan, M.D., Ph.D. and Scott Hancock, Health Canada, Feb. 21, 2019
F4	Email Exchange between Ghassan Saed, Ph.D. and Scott Hancock, Health Canada, Feb.-Mar. 2019
F5	Email Exchange between Jack Siemiatycki, M.Sc., Ph.D. and Scott Hancock, Health Canada, Mar. 2019


Section G: Documents Relating to Dr. Saed's Lab Notebooks	
Exhibit No.	Description
G1	Plaintiffs' Steering Committee's Responses & Objections to the Notice of Dep. of Ghassan M. Saed, Ph.D. & Duces Tecum, Dec. 20, 2018
G2	Letter from P. Leigh O'Dell to Hon. Joel A. Pisano, Dec. 27, 2018
G3	Letter from Susan M. Sharko to Hon. Joel A. Pisano, Jan. 25, 2019
G4	Letter from Daniel R. Lapinski to Hon. Joel A. Pisano, Jan. 31, 2019
G5	Letter from Hon. Joel A. Pisano to Counsel, Feb. 5, 2019
G6	Letter Opinion from Hon. Joel A. Pisano to All Counsel of Record, Apr. 26, 2019

Section H: Plaintiffs' Requests for Baby Powder Formula Documents	
Exhibit No.	Description
H1	Letter from Chris Tisi to Susan Sharko, Aug. 30, 2018
H2	Exhibits 1-3 to Response Email from Richard T. Bernardo to Chris Tisi, Oct. 16, 2018 [FILED UNDER SEAL Pursuant to Discovery Confidentiality Order dated March 1, 2017]

Section I: Miscellaneous MDL Documents	
Exhibit No.	Description
I1	2-TalcDataResults-janehall.xlsx produced by plaintiffs prior to the deposition of Rebecca Smith-Bindman
I2	Email Exchange between Susan Sharko and P. Leigh O'Dell, Feb.-Mar. 2019
I3	Plaintiffs' Steering Committee's Initial Designation & Disclosure of Non-Case Specific Expert Witnesses

3. I certify that the foregoing statements made by me are true. I am aware that if any of the foregoing statements made by me are willfully false, I may be subject to punishment.

Dated: May 7, 2019


Julie L. Tersigni